Clinical Trial Detail

NCT ID NCT03975231
Title Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Manisha Shah
Indications

thyroid gland cancer

Therapies

Dabrafenib + Trametinib

Age Groups: adult senior

Additional content available in CKB BOOST